Seth Pollack, MD
Enriched profileSteven T. Rosen, MD, Professor of Cancer Biology; Professor of Medicine (Hematology and Oncology); Director, Sarcoma Program, Robert H. Lurie Comprehensive Cancer Center · Northwestern University Feinberg School of Medicine
Seth Pollack is Steven T. Rosen, MD, Professor of Cancer Biology; Professor of Medicine (Hematology and Oncology); Director, Sarcoma Program, Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine. OpenAlex indexes 303 publications with 5,158 citations (h-index 35); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Seth Pollack, MD, is Steven T. Rosen, MD, Professor of Cancer Biology at Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The public record shows 303 publications with 5,158 citations (h-index 35), centered on Sarcoma Diagnosis and Treatment, CAR-T cell therapy research, Immunotherapy and Immune Responses. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 10 companies, 4 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Sarcoma Diagnosis and Treatment
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 72.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
Sponsor: USWM CT, LLC
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 1 Sept 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SpringWorks Therapeutics, Inc.Program year202519 payments$25,773openpaymentsdata.cms.gov ↗
- Deciphera Pharmaceuticals Inc.Program year202517 payments$13,533openpaymentsdata.cms.gov ↗
- EMD Serono, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.6%PD-1 inhibitor29.8%Nivolumab100%Part B, office-administered≥11 patientsCD38-directed Cytolytic Antibody16.8%Daratumumab100%Part B, office-administered≥14 patientsDermatology
20.7%Corticosteroid20.7%Methylprednisolone sodium succinate100%Part B, office-administered≥31 patientsMetabolism & gastrointestinal
17.4%Other antiemetics14.7%Fosaprepitant100%Part B, office-administered≥18 patientsSerotonin-3 Receptor Antagonist2.7%Palonosetron hcl58%Granisetron hydrochloride42%Part B, office-administered≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
4 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
Northwestern University
FY2026$657,844R01CA290719 - Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV
Northwestern University
FY2026$652,313R01CA298377 - Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
Northwestern University
FY2025$672,844R01CA290719
Congress activity
Updated 1 Sept 2026
50 congress contributions (2007–2026) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Abstract A037: Molecular characterization of adult small round blue cell tumors reveals frequent non-classical EWSR1 and related rearrangements
AACR (meeting unresolved)
AACR2026Co-author - Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.
Cancer immunology research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyArticle1,167 citations2022
- 02
- 03
- 04
- 05
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/seth-pollack-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Seth-Pollack
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/immunosarc
Mentions by others
where others cite or feature them- Facebook
facebook.com/NWSarcoma/videos/interview-with-dr-seth-pollack/1128304000550979
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/sarc-talk/id1655201709
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board Certified
Medical Oncology (American Board of Internal Medicine)
Editorial & leadership roles
journal and society appointments- Session chair at annual meetings of ASCO
JSMO, and CTOS; keynote speaker, 2019 British Sarcoma Group Annual Meeting
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.northwestern.edu ↗ - Member
NCCN Clinical Practice Guidelines panel for Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.northwestern.edu ↗ - Lead author
invited review on sarcoma immunotherapy for Journal of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.northwestern.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.feinberg.northwestern.edu ↗
- Sig Kohl Legacy Award
Northwest Sarcoma Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.northwestern.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.northwestern.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Center for Human Immunobiology, Feinberg School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →feinberg.northwestern.edu ↗ - Co-Leader
Cancer Immunology and Immunotherapy Initiative, Robert H. Lurie Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - Advisory Board member
Desmoid Tumor Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dtrf.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- Featured guest
SARC Talk Podcast (SARC Sarcoma Clinical Trials)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sarctrials.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Martin Tallman, MD
Northwestern University Feinberg School of Medicine
Al Benson, MD
Northwestern University Feinberg School of Medicine
Sanjiv Shah, MD
Northwestern University Feinberg School of Medicine
Sadiya Khan, MD
Northwestern University Feinberg School of Medicine